Frontlight ResearchEarly access
Taking peoplePhase 2
Long-term study of IMVT-1402 in adults with Graves' disease
Tests IMVT-1402 over a longer period in adults with Graves' disease.
Key facts
- Who runs it
- Immunovant Sciences GmbH
- Where
- Dresden, Freiburg im Breisgau, Munich, Schwerin, and Wuerzburg, GermanySee the 5 sitesAlso in 10 other countries, 98 sites
- Trial code
- Registry title
- A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 128 people, planned
- Started
- 11 Jun 2026
- Expected to end
- 30 Mar 2030
- Type of study
- Interventional
- Record updated
- 10 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Graves' disease who completed Study IMVT-1402-2502 or Study IMVT-1402-2503. It follows how well IMVT-1402 works over the long term.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Graves' disease (an overactive thyroid caused by the immune system)
- Earlier treatment
- People must have completed Study IMVT-1402-2502 or Study IMVT-1402-2503.
Main reasons for not taking part
- Stopped the study drug for good during the treatment period of the earlier study
- Met the stopping rules of the earlier study at any time while taking part in it
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Participants who completed Study IMVT-1402-2502 or Study IMVT-1402-2503
Who cannot take part
- Have permanently discontinued IMP during the treatment period in the feeder study or have met study stopping criteria at any point up until the end of participation in the feeder study
Where in Germany
Also in 10 other countries, 98 sites
- Technische Universitaet DresdenDresden, GermanyNot yet recruiting
- Medical Center- University of FreiburgFreiburg im Breisgau, GermanyNot yet recruiting
- Medicover Medizin gGmbHMunich, GermanyNot yet recruiting
- HELIOS Kliniken Schwerin GmbHSchwerin, GermanyNot yet recruiting
- Universitaetsklinikum Wuerzburg AöRWuerzburg, GermanyNot yet recruiting
About the trial
What the trial wants to find out
To evaluate the efficacy of IMVT-1402 as assessed by maintenance of euthyroidism, off ATD, and off IMVT-1402 for 52 weeks in Group A Participants
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease
- Plain-language title
- Long-term study of IMVT-1402 in adults with Graves' diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 10 August 2026